Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases

[1]  D. Henson,et al.  Malignant Diffuse Mesothelioma in Women: A Study of 354 Cases. , 2020, The American journal of surgical pathology.

[2]  S. Armato,et al.  EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  V. Roggli,et al.  Malignant Diffuse Mesothelioma in Women , 2019, The American journal of surgical pathology.

[4]  J. Aerts,et al.  Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study , 2019, Annals of Surgical Oncology.

[5]  V. Roggli,et al.  Mesothelioma of the tunica vaginalis testis. , 2019, Human pathology.

[6]  N. Le Stang,et al.  Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: A population-based study. , 2019, Cancer epidemiology.

[7]  J. Chabot,et al.  50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience , 2019, Annals of Surgical Oncology.

[8]  Dongliang Yang,et al.  Significance of EGFR and PTEN Expression and PLR and NLR for Predicting the Prognosis of Epithelioid Malignant Peritoneal Mesothelioma , 2019, Gastroenterology research and practice.

[9]  Faraz Hach,et al.  BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma , 2018, Genome Medicine.

[10]  Liu Chun-rong,et al.  IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma. , 2018, Human pathology.

[11]  C. Simone,et al.  Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival , 2018, Annals of Surgical Oncology.

[12]  M. Simone,et al.  Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry , 2018, Annals of Surgical Oncology.

[13]  F. Galateau-Sallé,et al.  Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study , 2018, Modern Pathology.

[14]  A. Krasinskas,et al.  Reproducibility for histologic parameters in peritoneal mesothelioma. , 2017, Human pathology.

[15]  N. Le Stang,et al.  BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  K. Geisinger,et al.  A Histomorphologic Grading System That Predicts Overall Survival in Diffuse Malignant Peritoneal Mesothelioma With Epithelioid Subtype , 2016, The American journal of surgical pathology.

[17]  N. van Zandwijk,et al.  Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972–2009 , 2016, Australian and New Zealand journal of public health.

[18]  M. Deraco,et al.  The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) , 2016, Annals of Surgical Oncology.

[19]  A. Krasinskas,et al.  Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma , 2016, Histopathology.

[20]  V. Roggli,et al.  Sarcomatoid Peritoneal Mesothelioma: Clinicopathologic Correlation of 13 Cases , 2015, The American journal of surgical pathology.

[21]  T. Chua,et al.  Prognostic Significance of Ki67 Expression in Malignant Peritoneal Mesothelioma , 2015, American journal of clinical oncology.

[22]  V. Prasad,et al.  Distinctive clinical characteristics of malignant mesothelioma in young patients , 2015, Oncotarget.

[23]  P. Sugarbaker,et al.  Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent or Progressive Diffuse Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics and Survival Outcome , 2015, Annals of surgical oncology.

[24]  F. Johnston,et al.  Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis , 2015, Annals of Surgical Oncology.

[25]  M. Deraco,et al.  Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray , 2015, Annals of Surgical Oncology.

[26]  A. Burke,et al.  Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients , 2014, Pathology.

[27]  R. Bertulli,et al.  Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). , 2013, European journal of cancer.

[28]  T. Chua,et al.  Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. , 2013, American journal of cancer research.

[29]  T. Chua,et al.  MUC1 has Prognostic Significance in Malignant Peritoneal Mesothelioma , 2013, The International journal of biological markers.

[30]  E. Cotte,et al.  Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study , 2013, Annals of Surgical Oncology.

[31]  S. Libutti,et al.  Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. , 2013, Surgery.

[32]  N. Ordóñez.  Deciduoid mesothelioma: report of 21 cases with review of the literature , 2012, Modern Pathology.

[33]  T. Chua,et al.  Importance of gender in diffuse malignant peritoneal mesothelioma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  C. Sima,et al.  A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma , 2012, Modern Pathology.

[35]  G. Serio,et al.  High Wilms’ tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelioma , 2012, Histopathology.

[36]  D. Henderson,et al.  Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review , 2008, Modern Pathology.

[37]  E. Brun,et al.  Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. , 2006, Archives of pathology & laboratory medicine.

[38]  E. Brun,et al.  Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma† , 2006, Annals of Surgical Oncology.

[39]  P. Casali,et al.  Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion , 2006, Annals of Surgical Oncology.

[40]  P. Casali,et al.  Diffuse malignant mesothelioma of the peritoneum , 2005, Cancer.

[41]  A. Borczuk,et al.  P16 Loss and Mitotic Activity Predict Poor Survival in Patients with Peritoneal Malignant Mesothelioma , 2005, Clinical Cancer Research.

[42]  Seth M Steinberg,et al.  Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  P. Clement,et al.  Diffuse malignant epithelial mesotheliomas of the peritoneum in women , 2002, Cancer.

[44]  P. Sugarbaker,et al.  Peritoneal mesothelioma proposal for a staging system. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[45]  B. Shmookler,et al.  Results of treatment of 33 patients with peritoneal mesothelioma , 2000, The British journal of surgery.

[46]  P. Clement,et al.  Malignant mesotheliomas presenting as ovarian masses. A report of nine cases, including two primary ovarian mesotheliomas. , 1996, The American journal of surgical pathology.

[47]  J. Goldblum,et al.  Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors. , 1995, The American journal of surgical pathology.

[48]  J. Noble,et al.  Mesothelioma of the tunica vaginalis of the testis. , 1992, British journal of urology.

[49]  A. Gupta,et al.  Malignant peritoneal mesothelioma. , 1977, Journal of the Indian Medical Association.

[50]  T. Giles,et al.  Diffuse Malignant Mesothelioma of the Peritoneum , 1967, Southern medical journal.

[51]  A. Krasinskas,et al.  The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma , 2016, Modern Pathology.

[52]  H. Pass,et al.  Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. , 2015, Carcinogenesis.

[53]  F. F. Paul H. Sugarbaker MD,et al.  Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent or Progressive Diffuse Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics and Survival Outcome , 2014, Annals of Surgical Oncology.

[54]  S. Ahrendt,et al.  Malignant Peritoneal Mesothelioma: Prognostic Factors and Oncologic Outcome Analysis , 2013, Annals of Surgical Oncology.

[55]  F. Ricceri,et al.  Survival of peritoneal malignant mesothelioma in Italy: A population‐based study , 2009, International journal of cancer.

[56]  Vincenzo De Pangher Manzini.  Malignant peritoneal mesothelioma. , 2005 .

[57]  R. Shemin,et al.  Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  D. E. Jones,et al.  Peritoneal mesotheliomas. , 1979, Surgery.